SCHEMBL23726224

SCHEMBL23726224

O=Cc1ccc(Br)nc1F

nearest known ligand 0.39

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.36
TRIM33 Q9UPN9 1/20 0.36
TDP1 Q9NUW8 2/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
THRB P10828 1/20 0.33
BLM P54132 1/20 0.33
KMT2A Q03164 1/20 0.33
ERN1 O75460 2/20 0.32
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31520815 1.00 TRIM24 (0.36) TRIM24TRIM33TDP1MEN1LMNA
SCHEMBL623439 0.77 TDP1 (0.36) TRIM24TRIM33TDP1MEN1LMNA
SCHEMBL29438802 0.77 TDP1 (0.36) TRIM24TRIM33TDP1MEN1LMNA
SCHEMBL29906624 0.77 TRIM24 (0.48) TRIM24TRIM33TDP1MEN1LMNA
SCHEMBL3102823 0.77 TRIM24 (0.48) TRIM24TRIM33TDP1MEN1LMNA
SCHEMBL4597958 0.76 ALDH1A1 (0.38) TRIM24TRIM33TDP1MEN1LMNA
SCHEMBL3509732 0.74 TDP1 (0.39) TDP1MEN1LMNATHRBBLM
SCHEMBL15873266 0.74 TRIM24 (0.36) TRIM24TRIM33TDP1MEN1LMNA
SCHEMBL23725196 0.74 ERN1 (0.41) TRIM24TRIM33TDP1MEN1LMNA
SCHEMBL15940534 0.74 ALDH1A1 (0.44) TRIM24TRIM33TDP1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062427-A1 Bicyclic Ureas As Kinase Inhibitors INCYTE CORP (US) 2026-03-05 US disclosed
US-20260042781-A1 Bicyclic Ureas As Kinase Inhibitors INCYTE CORP (US) 2026-02-12 US disclosed
WO-2025096706-A1 MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-05-08 WO disclosed
WO-2024188288-A2 SMALL MOLECULE MODULATORS OF IL-17A, METHODS OF MAKING AND METHODS OF USING THEREOF Ascletis BioScience Co., Ltd (CN) 2024-09-19 WO disclosed
US-20230357199-A1 ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. 2023-11-09 US disclosed
US-20230357199-A1 ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. 2023-11-09 US disclosed
US-11708351-B2 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-07-25 US disclosed
US-11708351-B2 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-07-25 US disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
EP-4100381-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2022-12-14 EP disclosed
CN-115413275-A Substituted 1,1 , -biphenyl compounds and methods of use thereof 爱彼特生物制药公司 2022-11-29 CN disclosed
CN-114195789-B Preparation method of polycyclic indole derivative without participation of metal 广东海洋大学 2022-09-09 CN disclosed
CN-114195789-A Preparation method of polycyclic indole derivative without metal participation 广东海洋大学 2022-03-18 CN disclosed
WO-2021158481-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2021-08-12 WO disclosed
US-20170166543-A1 COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) 2017-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708351-B2 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders CFD, TFPI, CFH TRIM24 4226/4885TRIM33 4021/4885TDP1 4535/4885
US-20230357199-A1 ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS CFD, TFPI, CFH TRIM24 4226/4885TRIM33 4021/4885TDP1 4535/4885
US-20170166543-A1 COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER PTMS, LTA, LPXN TRIM24 2735/4885TRIM33 1567/4885TDP1 2375/4885
US-20260042781-A1 Bicyclic Ureas As Kinase Inhibitors NR0B1, NR2C2, ERBB2 TRIM24 2477/4885TRIM33 4023/4885TDP1 3704/4885
US-20260062427-A1 Bicyclic Ureas As Kinase Inhibitors OXSR1, NCOR1, NR0B1 TRIM24 2270/4885TRIM33 3934/4885TDP1 3082/4885
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME HAVCR2, HMBS, VHL TRIM24 2052/4885TRIM33 1456/4885TDP1 1060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.